Monitor for updates on the CMO search and any interim leadership assignments, particularly given Vir's focus on clinical-stage biologics. The departure may prompt investor questions about continuity in medical strategy.
VIR drugs
VIR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $9.31entry
- T+1 · 7mo ago +7.95%α +6.74% · $10.05
- T+5 · 7mo ago +19.12%α +15.82% · $11.09
- T+20 · 6mo ago −0.21%α −7.94% · $9.29
- T+60 · 4mo ago +12.03%α +3.11% · $10.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vir Biotechnology's Chief Medical Officer, Mark Eisner, is stepping down effective April 24, 2026, and the company has begun a search for his successor. This is a C-suite departure but no immediate replacement was named.
Key Facts
- Dr. Mark Eisner, Executive Vice President and Chief Medical Officer, is stepping down effective April 24, 2026.
- He informed the company of his departure on April 7, 2026.
- The company has initiated a search for a successor but has not named an interim or permanent replacement.
- No reason for departure was specified beyond 'stepping down'.
Financial Impact
No direct financial impact disclosed; potential for near-term operational uncertainty in clinical development leadership.
Risk Factors
- Potential disruption in clinical development leadership during transition
- Increased scrutiny on management stability given recent insider selling
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-151209 |
| Document: 0001193125-26-151209-index-headers.html | 0001193125-26-151209 |
| Document: 0001193125-26-151209-index.html | 0001193125-26-151209 |
| Document: 0001193125-26-151209.txt | 0001193125-26-151209 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers